What we do
Building a multi-disciplinary community of trusted experts to accelerate finding effective treatment for rare cancer patients
Support for clinical trials
The prospective dataset will initially be collected from patients participating in clinical trials facilitated by Yamicc across multiple hospitals.
An example is the ReDiReCCT-GB trial, a trial within Erasmus MC which has recently started. In this clinical trial, in principle, every new patient diagnosed with glioblastoma will participate and be followed from diagnosis onward. Each patient’s tumor will be fully genetically profiled to determine whether a suitable drug is available based on the individual genetic profile.
We will also investigate whether promising drugs can effectively reach the tumor cells, using a new biological model to test which treatment is most likely to work for each patient. As part of this process, existing drugs that have already proven effective against other types of cancer will be tested on a large scale, a strategy known as drug repurposing. This approach is a key component in achieving improved and personalized treatments in a cost-effective way.
Yamicc Platform: our Trial Execution Platform for research
The Yamicc Platform is a shared, scalable, and reusable platform for conducting clinical studies on (rare) forms of cancer. We are building the platform together with hospitals, researchers, and partners. Step by step, practice-oriented, and with a focus on what truly works.
It significantly reduces both time and effort, from study setup to data analysis, ultimately leading to more research and more effective treatments.
Benefits for users of the Yamicc Platform
In addition to its societal impact, the Yamicc Platform offers direct benefits for hospitals, researchers, and research groups. By significantly reducing time-consuming and costly processes and making collaboration structurally easier, we make clinical research more efficient and practically feasible.
• Lower costs per study
By automating repetitive processes using technologies such as AI, we reduce manual work and operational workload. This makes studies more efficient and more affordable. Less manual work = lower costs. As a result, trials become feasible in places where this was previously impossible.
• Automated data collection
The Yamicc Platform supports hospitals and researchers in collecting data automatically. That means fewer errors, less manual work, less post-processing, and higher data quality from the start. Thanks to AI-driven automation, data can be made available in multiple formats and truly Interoperable and Reusable (FAIR).
• Acceleration of clinical research
A clinical study that can start faster will deliver results sooner. The platform shortens the time from design to execution and from discovery to application for the patient. By removing bottlenecks and facilitating collaboration across hospitals, trials can start earlier and generate outcomes faster.
Partnerships and Ecosystem
Uniting an ecosystem to accelerate progress.
At Yamicc, collaboration is key.
We bring together hospitals, research institutions, technology partners, cancer organizations, and patient advocacy groups, all working toward one shared mission: finding effective treatments for rare cancers.
Through our partner program, we connect new organizations and support existing partners in using and expanding our data-driven research platform.
By combining medical expertise, innovative technology, and a shared sense of purpose, we create the conditions for collaboration to thrive, making research faster, smarter, and more impactful for patients everywhere.
